Back to browse

EXP001743

Paper

Renal-targeting peptide-microRNA nanocomplex for near IR imaging and therapy of renal ischemia/reperfusion injury (2021)

Peptide

FA-R9-FPcas-3 (FMN-17 carrier peptide)

Sequence: FA-(Arg)9-(click-linker)-Ac-DEVD-PABA-mCy (NIR dye)

RNA

miRNA mimic

All experiment fields

Experiment Id EXP001743
Paper Renal-targeting peptide-microRNA nanocomplex for near IR imaging and therapy of renal ischemia/reper
Peptide FA-R9-FPcas-3 (FMN-17 carrier peptide)
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed yes
Label Confidence high
In Vitro Functional Effect yes
Endosomal Escape Evidence
Peptide Concentration Typically 4 mM peptide carrier in formulations (as reported for imaging/uptake conditions); flow cytometry used 20 µM FMN-17 for 24 h in apoptosis assay
Rna Concentration 100 nM miRNA mimic (typical in vitro transfection);
Mixing Ratio Peptide:miRNA molar ratios tested 10:1–40:1; commonly 20:1 for FMN-17
Formulation Format Self-assembled peptide/miRNA nanocomplex (FMN)
Formulation Components FA-R9-FPcas-3 peptide + miR-17-5p mimic (self-assembled FMN-17)
Size Nm 200.00
Zeta Mv 5.00
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells HK-2 human renal tubular epithelial cells (H/R model); selectivity assessed vs FHS74INT (intestinal) and L-O2 (hepatic) cells
Animal Model
Administration Route
Output Type in vitro functional effect (anti-apoptosis + caspase-3 activity imaging)
Output Value In HK-2 hypoxia/reoxygenation model, FMN-17 increased intracellular miR-17-5p and reduced apoptosis (Annexin V/PI, TUNEL), downregulated cleaved caspase-3, reduced ROS and urinary NAG; lower NIR turn-on signal consistent with reduced caspase-3 activation.
Output Units
Output Notes Best delivery at peptide:miRNA molar ratios around 20:1 (qPCR). Confocal shows intracellular Cy3-miRNA signal with LysoTracker staining (uptake). Nanocomplex size ~200–300 nm with zeta ~−5 to +8 mV across ratios; TEM shown for one ratio.
Toxicity Notes No strong cytotoxicity reported for FMN-17 at working concentrations; compared against Lipofectamine controls in miRNA delivery.
Curation Notes